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Among numerous cytokines modulating natural killer (NK) cell function, interleukin 15
(IL-15) exerts a broad range of effect from development and homeostasis, to activation
of mature NK cells during infection. Its significance is further highlighted by clinical trials
in which IL-15 is being used to boost the proliferation and anti-tumor response of NK
cells. Among the signal transduction pathways triggered by the engagement of IL-15
receptor with its ligand, the PI3K–AKT–mTOR pathway seems to be critical for the
IL-15-mediated activation of NK cells, therefore being responsible for efficient anti-viral
and anti-tumor responses. This review provides an overview of the role of IL-15 at multiple
stages of NK cell life journey. Understanding the pathway by which IL-15 conveys critical
signals for the generation of NK cells with efficient effector functions, in combination with
established protocols for NK cell expansion ex vivo, will undoubtedly open new avenues
for therapeutic applications for immunomodulation against infections and cancers.
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Introduction
Natural killer (NK) cells play critical roles in innate immune responses mainly against intracellular
viruses and tumors (1–3). The term NK was originally derived from the observation that they are
poised to kill target cells without prior sensitization or further differentiation (4, 5). Even though
recognition receptors that target infected cells are germline-encoded with restricted recognition
compared to T and B cell receptors, the mechanism of NK cell cytotoxicity against virus-infected
cells is similar to that of CD8+ cytotoxic T lymphocytes (CTL). NK cells induce perforin/granzyme-
dependent apoptosis in target cells and thereby eliminate reservoirs of virus replication (2, 3, 6).
For this, NK cells express an array of inhibitory and activating receptors, which receive multiple
stimuli from virus-infected cells. The balance between signals that are generated from activating
receptors and inhibitory receptors mainly determines the immediate cytotoxic activation. NK cell
activation also induces cytokine secretion such as IFN-γ and TNF-α. These cytokines enhance the
phagocytic function of macrophages and their antimicrobial activity, and augment the adaptive
immune response via up-regulation of antigen presentation by antigen presenting cells such as
dendritic cells (DCs) (2, 7).
In addition to signals from bothNK cell activating and inhibitory receptors, signals from cytokine
receptors on NK cells greatly modulate the development and activation of NK cells. Even though
cytokines can exhibit pleiotropic effects depending on the responding cell’s condition, IL-2, -12, -15,
-18, and -21 are regarded as being stimulators for NK cell function (8, 9) whereas TGF-β and IL-10
are known as negative regulators (9). Notably, IL-15 is the most potent among them by orchestrating
the entire life of NK cells and holds a great potential for immunotherapy in cancer and infectious
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research. Here, we will provide an overview of our knowledge
regarding the PI3K–AKT–mTOR pathway as a major IL-15-
mediated pathway driving the development, proliferation, and
effector functions of NK cells.
KEY CONCEPT 1 mTOR Pathway
Themammalian target of rapamycin (mTOR) is a serine/threonine protein kinase
that functions as a sensor of environmental nutrient availability, and translates
the information into cellular signals that regulate ribosomal biogenesis, protein
translation, cell growth, and cell proliferation.
Interleukin-15
IL-15 drew much attention due to its similarity to IL-2 in its
cytokine receptor biology. IL-15R is a heterotrimeric receptor
consisting of a unique α chain, a shared β subunit with IL-
2 (CD122) and a common γ subunit (CD132) shared with
several cytokines (10), implying similar biological activities of
IL-2 and IL-15. IL-2 was the first cytokine used in clini-
cal cancer trials due to its great ability to expand NK cells
and stimulate NK cell functions (11). However, severe toxic-
ity associated with the administration of IL-2 limited its appli-
cation. Recently, the clinical interest of using IL-15 was fur-
ther strengthened because IL-2 administration also expanded
regulatory T cells, which suppress the anti-tumor response of
NK cells and effector T cells (12–14). On the other hand, IL-
15 therapy resulted in low toxicity with expansion of NK cells
without expansion of Tregs in vivo, in a study of non-human
primates (15).
KEY CONCEPT 2 IL-15
IL-15 is a key cytokine exhibiting a pleiotropic effect on the development,
proliferation and activation of natural killer cells, as well as the proliferation and
activation in CD8+ T-cell, therefore being considered as one of most promising
molecules for anti-cancer immune therapy.
Studies have shown that IL-15-/- mice exhibit a selective
loss of memory phenotype CD8+ T cells, NKT cells, and NK
cells (10, 16, 17). A unique aspect of IL-15 is that it employs
trans-presentation in which IL-15-producing cells present the
cytokine in the context of IL-15 receptor α (IL-15Rα) chain on
the cell surface. A pivotal role of dendritic cell (DC)-expressed
IL-15Rα for trans-presenting IL-15 to NK cells has been
demonstrated (18, 19). Engagement of IL-15R on NK cells
causes the auto-phosphorylation and activation of Janus Kinases
(JAK1 and JAK3), which induces at least three parallel signaling
cascades: Ras–Raf–MAPK, signal transduction and activation
of transcription (STAT) 5 and PI3K–AKT–mTOR pathways (10,
20). The indispensable role of IL-15–STAT5 pathway for NK
cell development and homeostasis was also exemplified in mice
having defects in the signaling pathway in which the number
of mature NK cells was dramatically reduced (21–23). Data
from Stat5-deficient and NK cell-specific Stat5-deficient mice
showed that NK cells are absent in peripheral lymphoid organs,
suggesting a crucial role of the IL-15–STAT5 pathway in NK cell
development (21–23). In addition, similarly to STAT5 knock-out
mice, a severe reduction in NK cell numbers was found in a
patient carrying the STAT5bmutation (24).
PI3K–AKT–mTOR Pathway
In addition to the IL-15–STAT5 pathway, accumulating data
pointed out that the PI3K–AKT–mTOR pathway is essential
for modulating the development, differentiation, and activa-
tion of immune cells including NK cells. Signaling triggered by
cytokines employing the JAK–STAT pathway generally stimulates
the PI3K/AKT signaling pathway in immune cells (25). PI3K,
phosphatidylinositol 3-kinase, is conserved in allmammalian cells
and is known to control diverse processes including cell prolifera-
tion, survival, differentiation, activation of effector functions, and
metabolism (26, 27). Among three classes (I, II, and III), the class
I PI3Ks, which are heterodimeric enzymes consisting of a regula-
tory subunit (p85) and a catalytic subunit (p110), predominately
regulate downstream signals emanating from cytokine receptor
activation. Upon cytokines binding to their receptors, receptor
tyrosine kinases activate PI3K, which generates phosphatidyli-
nositol trisphosphate (PIP3) from plasma membrane-associated
phosphatidylinositol bisphosphate (PIP2). PIP3 has an affinity for
pleckstrin homology (PH) domain-containing molecules such as
AKT and phosphoinositide-dependent protein kinase (PDK1) on
the inner leaflet of the plasma membrane. At the plasma mem-
brane, the interaction between the PH domain of AKT and PIP3
induces important conformational changes in AKT, which allow
subsequent modifications of AKT at threonine 308 by PDK1.
mTORC2 also can phosphorylate AKT at serine 473 for further
activation (28).
Activated AKT phosphorylates crucial targets and contributes
to cell survival by inhibiting pro-apoptotic members of the Bcl-
2 family. One of the important downstream effectors for the
PI3K/AKT signaling is mTOR, which is a serine/threonine pro-
tein kinase required for the translation of proteins that promote
cell survival and proliferation. mTOR exists as two complexes,
mTORC1 and mTORC2. Even though mTORC2 can activate
mTORC1 by AKT phosphorylation, a metabolic reprograming
which supports effector T cell proliferation and functions has
been mainly investigated in the context of mTORC1 complex.
mTORC1 is negatively regulated by a heterodimeric protein com-
plex called tuberous sclerosis complex (TSC) 1 and 2. The TSC
inhibits mTORC1 by suppressing the conversion of Rheb-GDP
to Rheb-GTP, a small GTPase, required for mTORC1 activation.
PI3K–AKT signaling results in the phosphorylation and inacti-
vation of TSC2, which increases Rheb-GTP and mTORC1 kinase
activity (29–32). mTORC1 promotes the translation machinery
through the phosphorylation of the translation-initiation factor
eIF4E-binding protein (4EBP1), and the S6 ribosomal kinase
(S6K). Upon phosphorylation, the translation repressor protein
4EBP1 is dissociated from eIF4E, leading to the subsequent
formation of the translation initiation complex. S6K directly
phosphorylates several proteins implicated in protein transla-
tion including eukaryotic initiation factors and ribosomal protein
S6 (33). In addition, mTORC1 increases the rate of glycolysis
by inducing the expression of HIF-1α and c-Myc and nutrient
transporters (30).
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3552
Ali et al. IL-15–mTOR pathway in NK cells
FIGURE 1 | IL-15 response during natural killer cell development.
The developmental stages of mouse NK cells in the bone marrow and
periphery are shown, together with the IL-15R expression and IL-15
response. HSC, hematopoietic stem cell; CLP, common lymphoid




Mature NK cells are differentiated from common lymphoid pro-
genitors (CLPs). Even though NK cells can develop in extra-
medullary sites such as the thymus and liver, the developmental
program from CLPs to mature NK cells mainly occurs in the
bone marrow (34, 35). CLPs differentiate into NK cell progenitors
which are defined as Lin- NK1.1- CD122+ cells (36) and the
acquisition of IL-15R-β chain (CD122) is a critical step allowing
the progenitor cells to become responsive to IL-15 in the bone
marrow compartment (Figure 1). Interestingly, NK cell progen-
itors display high proliferative potentials which are dependent on
IL-15. Several studies from immune cell-specific deficient mice or
in vitro NK cell differentiation identified factors responsible for
the IL-15-mediated development process (35, 37).
Several identified factors are required for the acquisition
and maintenance of CD122 on NK cell progenitors. The T-
box transcription factor Eomes (also known as Eomesoder-
min) was shown to bind the CD122 promoter region, and the
expression of CD122 on NK cells and memory CD8+ T cells
from Eomes-deficient mice was significantly lower resulting in
reduced responsiveness to IL-15 (38). The basic leucine zip-
per transcription factor E4BP4 (also known as Nfil3) seems to
function upstream of Eomes, so that E4BP4 deficiency caused
severe defects in NK cell development (39, 40). A recent paper
demonstrated that PDK1, a kinase downstream of PI3K and
upstream of mTOR, functions as a critical component in the
positive feedback loop (41). Rescue of the defect of PDK1 by
ectopic expression of E4BP4 or Eomes suggests that PDK1 sig-
naling is critical for NK cell development via induction of
E4BP4 and Eomes. Therefore, the IL-15 positive feedback loop
might involve IL-15–PDK1–mTOR–E4BP4-Eomes–high levels of
CD122-enhanced IL-15 signaling (Figure 1). The role of the
metabolic checkpoint kinase mTOR on controlling NK cell pro-
liferation in the bone marrow was also demonstrated in NK
cell-specific mTOR-deficient mice (Ncr1-Cre  Mtorlox) (42).
Consistently, a severe defect in early NK cell development
was also observed in mice deficient in both the p110γ and
p110δ catalytic subunits of PI3K (43), suggesting that PDK1




The priming effect is based on the fact that exposure of IL-15 sen-
sitizes NK cells to secondary stimuli, thereby resulting in a height-
ened response. It is a physiologically relevant process because NK
cells are recruited to lymph nodes where they are first activated
by trans-presentation of IL-15 by IL-15Rα expressed on DCs (44)
during inflammation and stimulated by subsequent cytokines or
activating ligands. A well-known “priming” is exemplified by an
exaggerated IFN-γ response whenNK cells are co-stimulated with
IL-12, IL-18, and IL-15 ex vivo (44–46). In our previous work, we
demonstrate that the priming effect by IL-15 can be extended to
stimulation by most cytokines employing the JAK–STAT pathway
and ligands ofNK cell activation receptors (47).When the priming
effect is evaluated bymeasuring the phosphorylation of respective
STATs, the response to type I IFN, IL-21, IL-12, IL-2, and IL-
4 stimulation in NK cells primed by IL-15 was found greatly
enhanced compared to naïve NK cells. In addition, the IFN-γ
expression in primed NK cells after stimulation through Ly49H
activation receptor was increased.
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KEY CONCEPT 3 Priming Effect
The priming effect of cytokines refers to a phenomenon in which one cytokine
can increase the sensitivity of cells to stimulation with other cytokines, resulting
in an exaggerated response.
Several mechanisms have been proposed to explain the prim-
ing effect. Stimulation with IL-12 or IL-15 can induce the up-
regulation of IL-18R transcript in human naive CD56+ NK cells,
therefore enhancing the response to subsequent IL-18 exposure
and IFN-γ production (45, 48). In our study, PI3K–AKT–mTOR
pathway was identified as a principal pathway inducing the prim-
ing effect. Blocking of individual components of the pathway
using cell-permeable reversible inhibitors severely abrogates the
IL-15-mediated priming effects, as tested for, at least, IL-12-
induced phosphorylation of STAT4, IL-21-induced phosphoryla-
tion of STAT3, and Ly49H-induced IFN-γ production. One caveat
of using pharmacological inhibitors is that some inhibitors could
modulate off-targets. In particular, Ly294002, a common PI3K
inhibitor, has been known to induce non-specific effects, includ-
ing the direct inhibition of mTOR’s catalytic function (49). There-
fore, data obtained from experiments using Ly294002 should
be taken cautiously. Nonetheless, inhibitors used for blocking
AKT and mTOR in our study were generally regarded as highly
specific. It is noteworthy that the requirement of mTOR for
JAK–STAT activation might be extended to T cell regulation.
Similar to the diminished levels of phosphorylated STATs in
rapamycin-treated IL-15-primed NK cells, mTOR-deficient CD4
T cells fail to differentiate into Th1, Th2, and Th17 cells and this
defect was largely due to impaired phosphorylation of respective
STAT molecules required for each lineage differentiation (50).
Mechanisms by which the PI3K–AKT–mTOR pathway crosstalks
with the JAK–STAT pathway for inducing the priming effect are
still not clear. It would be interesting to investigate the role of
PI3K–AKT–mTOR pathway in the regulatory pathways of general
JAK–STAT signaling such as suppressor of cytokine signaling
(SOCS), protein inhibitors of activated STAT (PIAS), and protein
tyrosine phosphatases (PTPs) (51).
Recently, a new form of priming using IL-15, IL-12, and
IL-18 was suggested to generate memory-like NK cells which
show enhanced effector functions upon restimulation follow-
ing a 3-week resting period (52). This memory-like phenotype
was found in proliferating NK cells. Due to the long-lasting
and enhanced effector phenotype, studies that are trying to use
adoptive transfer of the memory-like NK cells pre-activated with
IL-12/-15/-18 for cancer immunotherapy (8, 53, 54) are being
carried out, and one group showed that adoptive transfer of
those pre-activated NK cells greatly increases the numbers and
effector functions of NK cells, resulting in pronounced tumor
regression in a mouse model of established tumor (53). One of
the mechanisms responsible for this prolonged and enhanced
tumor surveillance was mediated through IL-2Rα chain (CD25)
up-regulation induced by IL-12 and IL-18 stimulation, thereby
allowing NK cells to be sustained under the low physiological
levels of IL-2 (53, 55). Nonetheless, whether PI3K–AKT–mTOR
pathway is required to induce memory-like NK cells has not been
tested.
PI3K–AKT–mTOR Pathway for NK Cell
Proliferation During Virus Infection
During their differentiation in the bone marrow, NK cells hold a
great potential of proliferation. However, NK cells become gradu-
ally quiescent as they fully mature (Figure 1) (56, 57). Ample data
support that IL-15–JAK1/3-STAT5 is required for the homeostasis
and survival of peripheral mature NK cells (10, 58, 59). Since IL-
15 is essential for NK cell survival, cells deprived of IL-15 undergo
considerable death. When adoptively transferred to IL-15-/- mice,
mature splenic NK cells failed to be maintained, mainly due to
the inability to sustain sufficient levels of the anti-apoptotic Bcl-2
expression in vivo (60, 61). Moreover, in vivo antibody blocking
of IL-15R signaling also resulted in a severe loss of splenic NK
cells within a week. Consistent with the previously identified
indispensable role of IL-15-JAK1/3–STAT5, blocking of JAK and
STAT5 pathways resulted in significant cell death, similar to when
NK cells are deprived of IL-15. Notably, NK cells treated with
inhibitors for the PI3K–AKT–mTOR were still able to maintain
their viability similar to controls (cells without any inhibitor treat-
ment) in the presence of IL-15, suggesting that the pathway is
dispensable to support the survival of mature NK cells (47). The
dispensable role of mTOR for survival was further supported in
the study showing intact prosurvival signals provided by IL-15 in
mTOR-deficient NK cells (21, 42).
Mature peripheral NK cells can rapidly and intensively pro-
liferate during viral infections. The evidence for NK cells pro-
liferation during virus infections was first recognized by Biron
and colleagues three decades ago when they observed transient
NK cell blastogenesis characterized by increased cell mass and
proliferation at the onset of lymphocytic choriomeningitis virus
(LCMV) and murine cytomegalovirus (MCMV) infections (62–
64). Early on during the course of MCMV infection, blastoge-
nesis and proliferation of NK cell is dependent on IL-15 (65,
66) (Figure 2). The IL-15 trans-presentation and the resulting
activation of NK cells are dependent on type I IFN mainly
induced by TLR recognition of viral PAMP (44). Our study
pointed out that the PI3K–AKT–mTOR pathway is essential
for the proliferation of mature NK cells upon IL-15 stimula-
tion (47). Ex vivo IL-15 stimulation of splenic NK cell in the
presence of inhibitors for the pathway resulted in a dramatic
reduction of proliferation. The defect was consistently observed
in a broad range of IL-15 concentrations. To test the role of
the pathway in vivo, we decided to evaluate NK cell prolifera-
tion in mice treated with rapamycin to block mTOR pathway
during MCMV infection, where NK cell proliferation at early
infection is well reported. During MCMV infection, NK cells
show a peak proliferation response at days 2.5–3 post infection.
In line with ex vivo data, proliferation of NK cells as mea-
sured by BrdU incorporation was severely reduced in rapamycin-
treated mice during MCMV infection. This mTOR-dependent
NK cell proliferation has been reproduced in an independent
study showing that early proliferation during MCMV infec-
tion was greatly impaired in NK cell-specific mTOR-deficient
mice (42).
Yokoyama and colleagues proposed two stages of NK cell
proliferation consisting of pathogen-non-specific and -specific
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FIGURE 2 | Natural killer cell proliferation during murine cytomegalovirus
infection. During MCMV infection, two stages of NK cell proliferation showing
pathogen non-specific and specific responses have been proposed. IL-15 drives
NK cell proliferation during the early phase of MCMV infection. Upon recognition
of CpG motifs from MCMV viral DNA by TLR9, plasmacytoid dendritic cells
(pDCs) secrete type I interferons (IFNα/β) and interleukin-12 (IL-12) cytokines.
DC-derived IL-12 stimulates NK cells to produce IFN-γ. IFNα/β is transiently
produced and reaches a peak level at day 1.5 post-infection and the production is
important to induce the expression of IL-15. IL-15 is trans-presented by DCs to
NK cells to induce proliferation and enhanced effector functions of NK cells.
Activated NK cells can induce perforin/granzyme-mediated apoptosis of
MCMV-infected cells by recognizing the viral m157 protein on the cell surface.
This direct recognition depends on the activating receptor Ly49H. Proliferation at
this stage is dependent on the PI3K–AKT–mTOR pathway. The interaction
between Ly49H and the MCMV-encoded protein m157 drives the proliferation
and expansion of Ly49H+ NK cells on days 6–7 post infection. Notably, this
proliferation can occur in IL-15- and IL-15Rα-deficient mice during MCMV
infection and is independent of the PI3K–AKT–mTOR pathway.
proliferation during MCMV infection (57) (Figure 2). Following
the early IL-15-induced NK cell proliferation (first stage), the
proliferation can be extended to a later stage of preferential prolif-
eration of NK cells expressing the specific activating receptor that
recognizes a viral ligand on the infected cells (second stage). The
main example is the Ly49H-activating receptor that recognizes
theMCMV-encoded m157 glycoprotein onMCMV-infected cells
(67–71). This recognition induces perforin/granzyme-mediated
killing of the infected cells and confers NK cell-mediated resis-
tance to MCMV (2). During MCMV infection, Ly49H+ NK cells
display preferential proliferation and the expansion is blocked
by α-Ly49H antibody treatment, indicating that a stimulatory
signal through the Ly49H is responsible for the proliferation.
This pathogen-specific NK cell proliferation and expansion is
comparable to that of antigen-specific T cells during virus infec-
tion and shows a peak response on days 6 and 7 post infec-
tion (72). Analogous NK cell expansion has also been found
in other virus infections such as hantavirus, HCMV, and HIV
(73–75). Notably, NK cells in NK cell-specific mTOR-deficient
mice displayed substantial Ly49H-dependent proliferation at day
6.5, even though less proliferation was observed compared to
mTOR-sufficient NK cells (42). Therefore, mTOR pathway is
critical in IL-15-driven proliferation, but has a minimal role on
activating receptor-driven proliferation. Such IL-15-independent
and Ly49H-mediated NK cell proliferation has previously been
reported (76).
PI3K–AKT–mTOR Pathway for NK Cell
Effector Function During Virus Infection
Natural killer cells were originally regarded as “ready to kill”
cells that can immediately destroy virus-infected or transformed
cells (5, 77). However, unlike human NK cells, naïve mouse NK
cells derived from laboratory strains of mice housed in a specific
pathogen-free environment are devoid of perforin and granzyme
B cytotoxic granules and exhibit minimal effector functions (44,
78, 79). A report demonstrated that IL-15 can induce rapid trans-
lation of pre-existing perforin and granzyme B mRNAs in NK
cells in order to be fully equipped for action (78). Accordingly,
splenic NK cells are induced to express high levels of granzyme
B upon stimulation with IL-15 for 24 h. Notably, the granzyme
B induction was abrogated in the presence of inhibitors block-
ing the PI3K–AKT–mTORC1 pathway (47). Recent reports have
demonstrated that mTORC1 plays a major role in IL-15-induced
NK cell activation. mTORC1 activity is greatly increased in mice
treated with poly IC (a mimic of virus infection and inducer of
IL-15 expression) or infected with MCMV, as exemplified by the
drastic increase in the mTORC1-mediated phosphorylation of S6
ribosomal protein, a downstream target (42, 47, 80). Both phar-
macological inhibition and genetic ablation demonstrated that
mTORC1 is a non-redundantmetabolic regulator for NK cell acti-
vation, dictating proliferation, and effector functions upon poly
IC treatment (42, 80). Ablation of mTORC1 signaling reduced
blastogenesis, and inhibited the expression of effector molecules
such as IFN-γ and granzyme B.
To translate the importance of PI3K–mTOR pathway for
NK cell functions during virus infection, we treated mice with
rapamycin to block mTOR kinase activity downstream of PI3K
(30, 81). The treatment of rapamycin on NK cell functions during
MCMV infection also resulted in severe defects in IFN-γ and
granzyme B productions in addition to defects in proliferation.
Similar impairments were also observed in NK cells treated ex
vivo with inhibitors for activating kinases upstream of mTORC1
such as PI3K and AKT (47). It is well established that granzymes
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and IFN-γ are effector molecules required for the efficient anti-
viral activity of NK cells (82–85). Therefore, in vivo treatment
with the mTORC1 inhibitor rapamycin during MCMV infection
abrogated NK cell cytotoxicity toward YAC-1 tumor cells and
resulted in elevated viral loads in the infected organs (47). This
was accompanied by defective NK cell effector functions, thereby
coupling this important metabolic sensor to NK cell anti-viral
responses. Taken together, the results demonstrated the central
role of PI3K–AKT–mTORC1 pathway in IL-15-induced NK cell
activation of effector functions during virus infection.
During virus infection, activated NK cells must increase their
metabolic uptake to support blastogenesis and the accelerated cell
cycles. It includes elevated production of biomolecules such as
nucleic acids, proteins, and lipids accompanied by the increased
uptake of nutrients such as glucose and increased oxygen con-
sumption. The major role of IL-15 in the metabolic changes in
NK cells during virus infection was supported by the observa-
tion that up-regulated genes associated with metabolic pathways
are largely shared in microarray data of NK cells from mice
infected with MCMV in vivo or of NK cell treated with IL-15
in vitro (42). NK cells from both conditions induce increased
glucose uptake and increased expression of the nutrient recep-
tors CD71 (transferrin receptor) and CD98 (a component of
the -amino acid transporter). So how does IL-15 fulfill such
heightenedmetabolic demands inNK cells during virus infection?
Among the pathways activated upon IL-15 engagement, it seems
that the IL-15–PI3K–mTOR pathway is critical for the metabolic
reprograming. Whereas mTOR senses environmental nutrient
availability and translates the information into cellular responses
(50, 86, 87), it has become evident that mTOR-regulated cellular
metabolism plays a fundamental role in dictating immune cell
differentiation and function (88, 89). mTOR-regulated glycolysis
is also linked to the differentiation of activated CD4+ T cells
into anti-microbial Th1 and Th17 cells (50, 90, 91). In TCR-
stimulated CD8+ T cells, the PI3K–mTORC1 pathway was also
suggested to activate lipid synthesis for membrane biosynthesis
during blastogenesis (92).
Concluding Remarks
In this review, we have discussed how the IL-15–PI3K–mTOR
signaling pathway controls distinct stages of NK cell life cycle.
Accumulated evidence demonstrated that the signaling axis of
IL-15–PI3K–mTOR in NK cells is important for their develop-
ment, cellular proliferation, responsiveness to cytokine stimula-
tions, and cytotoxic functions. mTOR is a key regulator of cell
growth and metabolism and also provides a link between the
metabolism and effector functions of immune cells. IL-2/IL-15
share the receptor subunits IL-2/IL-15R-β and -γ chains and
both are being widely used for ex vivo expansion of NK cells
in immunotherapy. Their promising therapeutic capacity for a
variety of human malignancies has stimulated an interest in
using NK cells for anti-cancer treatments (93, 94). Recently, IL-
15 rather than IL-2 is the preferred cytokine for expanding NK
cells in vivo due to the minimal concern about toxicity and
expansion of Treg (95). Therefore, understanding the molecular
mechanisms by which IL-15 primes and activates NK cells will
allow the manipulation of IL-15 signaling for improving NK
cell-based therapeutic strategies against cancers and infectious
diseases.
Interestingly, even though the IL-15–PI3K–AKT–mTOR path-
way regulates multiple processes for NK cell biology from
development in the bone marrow to activation in the periph-
ery, some factors such as E4BP4 and PDK1 required for IL-
15-mediated development stages of NK cells are dispensable
for differentiation, survival, or effector function of mature NK
cells (39, 95, 96). Therefore, it suggests that additional signal-
ing modules might need to incorporate with the common IL-
15–PI3K–AKT–mTOR pathway in order to induce stage-specific
processes in NK cells.
The NK cell proliferation, cytokine production, and cytotoxic-
ity are dependent on the metabolic induction of mTOR pathway
during virus infection (42, 47, 80). Therefore, understanding the
metabolic program utilized by NK cells will guide the devel-
opment of optimal NK cell-mediated therapeutic interventions.
Such metabolic modulations on immune cells have been used to
induce enhanced CD8+ T cell memory responses. For instance,
treatment of rapamycin reduces glycolysis and promotes the lipid
metabolic program (50, 97), which is favorable for the generation
of memory CD8+ T cells (98–100); therefore suggesting its poten-
tial application to enhance vaccine efficacy against viruses. The
study of the metabolic regulation of NK cells is still in its infancy
compared to works established in T cells. Our current knowl-
edge has been mainly limited to cell culture experiments in vitro;
therefore translation of these findings for in vivo immunother-
apy warrants caution and careful interpretation. Without any
doubt, modulating the immune responses by manipulating cel-
lular metabolic pathways may provide an innovative option for
cancer immunotherapy.
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